
## Juan Ambrosioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2361719/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Experiencia de un programa de profilaxis preexposición en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripción del perfil basal del usuario e identificación de oportunidades de mejora. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2023, 41, 24-28.	0.5	7
2	Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study. Sexuality Research and Social Policy, 2023, 20, 614-625.	2.3	4
3	Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Clinical Microbiology and Infection, 2022, 28, 610.e1-610.e7.	6.0	5
4	Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. Journal of Antimicrobial Chemotherapy, 2022, 77, 1133-1139.	3.0	27
5	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Scientific Reports, 2022, 12, 5250.	3.3	11
6	Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. Infectious Diseases and Therapy, 2022, 11, 1243-1251.	4.0	2
7	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. Infection, 2022, 50, 1321-1328.	4.7	15
8	HIV infection in the setting of PrEP: Development of antiretroviral resistance and breakthrough infection. Report of two cases in real-life. Enfermedades Infecciosas Y Microbiologia Clinica (English) Tj ETQqO	00rgB3T/O	verlock 10 Tf
9	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 83-88.	6.0	636
10	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, 76, 2988-2992.	3.0	1
11	Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices. Infectious Diseases and Therapy, 2021, 10, 575-581.	4.0	11
12	Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017). Mayo Clinic Proceedings, 2021, 96, 132-146.	3.0	17
13	Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV,the, 2021, 8, e166-e174.	4.7	23
14	Mycobacterium Wolinskyi: A New Non-Tuberculous Mycobacterium Associated with Cardiovascular Infections?. Infectious Diseases and Therapy, 2021, 10, 1073-1080.	4.0	1
15	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case–Control Study. Infectious Diseases and Therapy, 2021, 10, 955-970.	4.0	2
16	Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review. Infectious Diseases and Therapy, 2021, 10, 1055-1064.	4.0	3
17	Infective Endocarditis in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2021, 77, 1629-1640.	2.8	23
18	Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. Infectious Diseases and Therapy, 2021, 10, 1253-1266.	4.0	10

#	Article	IF	CITATIONS
19	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305.	4.7	129
20	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infectious Diseases and Therapy, 2021, 10, 1407-1418.	4.0	5
21	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open, 2021, 11, e040775.	1.9	3
22	Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0252220.	3.2	2
23	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. Journal of Antimicrobial Chemotherapy, 2021, 76, 3296-3302.	3.0	30
24	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	4.4	8
25	Guillain-Barré-like syndrome as a rare presentation of severe primary HIV-infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 533-534.	0.5	3
26	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV,the, 2021, 8, e701-e710.	4.7	69
27	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. Infectious Diseases and Therapy, 2021, , 1.	4.0	6
28	HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. Current HIV/AIDS Reports, 2021, 18, 518-526.	3.1	10
29	Guillain-Barré-like syndrome as a rare presentation of severe primary HIV-infection. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2021, 39, 533-534.	0.3	3
30	HIV infection in the setting of PrEP: Development of antiretroviral resistance and breakthrough infection. Report of two cases in real-life. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 40, 280-280.	0.5	1
31	Diagnostic yield of 18F-FDG PET/CT in suspected diagnosis of vascular graft infection: A prospective cohort study. Journal of Nuclear Cardiology, 2020, 27, 294-302.	2.1	16
32	HIV-1 primary infection and acute hepatitis A: Beware of co-infection!. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2020, 38, 345-347.	0.3	0
33	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Medicine, 2020, 21, 617-624.	2.2	115
34	Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis. Journal of Antimicrobial Chemotherapy, 2020, 75, 3586-3592.	3.0	8
35	Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. Aids, 2020, 34, 1775-1780.	2.2	97
36	Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection. Aids, 2020, 34, 2269-2274.	2.2	8

#	Article	IF	CITATIONS
37	COVID-19 in patients with HIV $\hat{a} \in$ "Authors' reply. Lancet HIV,the, 2020, 7, e383-e384.	4.7	10
38	First imported case of tick-borne encephalitis in Spain – was it alimentary?. Travel Medicine and Infectious Disease, 2020, 37, 101701.	3.0	7
39	COVID-19 in patients with HIV: clinical case series. Lancet HIV,the, 2020, 7, e314-e316.	4.7	350
40	HIV-1 primary infection and acute hepatitis A: Beware of co-infection!. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 345-347.	0.5	0
41	Twenty-year experience with cryopreserved arterial allografts for vascular infectionsâ€. European Journal of Cardio-thoracic Surgery, 2019, 55, 358-365.	1.4	11
42	Infective endocarditis: an ongoing global challenge. European Heart Journal, 2019, 40, 3233-3236.	2.2	18
43	Acute liver failure due to visceral leishmaniasis in Barcelona: a case report. BMC Infectious Diseases, 2019, 19, 874.	2.9	9
44	Viral Sequences Detection by High-Throughput Sequencing in Cerebrospinal Fluid of Individuals with and without Central Nervous System Disease. Genes, 2019, 10, 625.	2.4	11
45	Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study. International Journal of Infectious Diseases, 2019, 88, 73-79.	3.3	5
46	Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
47	Role of age and comorbidities in mortality of patients with infective endocarditis. European Journal of Internal Medicine, 2019, 64, 63-71.	2.2	43
48	Effect of the type of surgical indication on mortality in patients with infective endocarditis who are rejected for surgical intervention. International Journal of Cardiology, 2019, 282, 24-30.	1.7	27
49	E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection. Aids, 2019, 33, 1613-1617.	2.2	5
50	New option for ART in patients with HIV on dialysis. Lancet HIV,the, 2019, 6, e2-e3.	4.7	0
51	Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort. Clinical Infectious Diseases, 2019, 69, 1690-1700.	5.8	44
52	Reply to Cuervo et al. Clinical Infectious Diseases, 2018, 67, 1146-1147.	5.8	0
53	The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	38
54	Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population. BMJ Open, 2018, 8, e018533.	1.9	17

#	Article	IF	CITATIONS
55	Mechanical Thrombectomy for Acute Ischemic Stroke Secondary to Infective Endocarditis. Clinical Infectious Diseases, 2018, 66, 1286-1289.	5.8	36
56	Epidemiology, Clinical Features, and Outcome of Infective Endocarditis due to Abiotrophia Species and Granulicatella Species: Report of 76 Cases, 2000–2015. Clinical Infectious Diseases, 2018, 66, 104-111.	5.8	40
57	Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment. JAMA - Journal of the American Medical Association, 2018, 320, 2153.	7.4	2
58	HACEK infective endocarditis: Epidemiology, clinical features, and outcome: A case–control study. International Journal of Infectious Diseases, 2018, 76, 120-125.	3.3	18
59	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 156, 248-264.	4.4	14
60	Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Brazilian Journal of Infectious Diseases, 2018, 22, 193-201.	0.6	13
61	Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
62	Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. Journal of Antimicrobial Chemotherapy, 2017, 72, 1548-1549.	3.0	2
63	Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection—authors' response. Journal of Antimicrobial Chemotherapy, 2017, 72, 1547-1548.	3.0	1
64	AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
65	Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Review of Anti-Infective Therapy, 2017, 15, 421-423.	4.4	4
66	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. Chest, 2017, 152, 295-303.	0.8	15
67	Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study. Journal of NeuroVirology, 2017, 23, 679-685.	2.1	4
68	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw462.	3.0	9
69	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2016, 62, 1578-1585.	5.8	5
70	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. Journal of Antimicrobial Chemotherapy, 2016, 71, 3195-3201.	3.0	11
71	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. Journal of Antimicrobial Chemotherapy, 2016, 71, 1125-1127.	3.0	7
72	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochemical Pharmacology, 2016, 106, 30-45.	4.4	50

#	Article	IF	CITATIONS
73	Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012). PLoS ONE, 2015, 10, e0125837.	2.5	23
74	Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. Journal of Clinical Virology, 2015, 64, 1-5.	3.1	23
75	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 2015, 63, 573-580.	3.7	46
76	The continuum of HIV care in Catalonia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 1449-1454.	1.2	14
77	Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS ONE, 2015, 10, e0131651.	2.5	5
78	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. PLoS ONE, 2015, 10, e0133879.	2.5	5
79	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	5.8	75
80	HIV treatment outcomes in Europe and North America: what can we learn from the differences?. Expert Review of Anti-Infective Therapy, 2014, 12, 523-526.	4.4	12
81	Update on antiretroviral treatment during primary HIV infection. Expert Review of Anti-Infective Therapy, 2014, 12, 793-807.	4.4	23
82	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. Aids, 2012, 26, 2079-2086.	2.2	47